OptiMedica CEO Mark Forchette tells MassDevice why femtosecond laser technology is changing the game in cataract surgery and how the promise of the technology lured him away from steady path at the largest ophthalmology company.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys cataract surgery system and CEO Mark Forchette isn't shy about extolling his company's potential.
The Catalys system, which won FDA clearance in December 2011 and CE Mark approval in the European Union in April 2012, performs cataract removal and intraocular lens placement using image-guidance and a next generation femtosecond laser clinically proven to be "an order of magnitude" more precise than manual cataract surgery.
"In the cataract space this is an incredible breakthrough that ultimately has tremendous potential to change the procedure not only now but for the future as well," Forchette told MassDevice. "And that sort of disruptive change process is in our corporate DNA."